News About: Pharm. Industry
What would be the reason why DPP-4 competition is so fierce?Handok has announced the launch of ‘Tenelia(generic name: teneligliptin),’ the 7th DPP-4 inhibitor. Its insurance price was selected as the lowest among other DPP-4 inhibitors w...
|
Kwang Dong Pharmaceutical challenges to the obesity treatment market with the best selling drug ‘Contrave’Kwang Dong Pharmaceutical(President Sung-won Choi) will enter the obesity treatment market.
Kwang Dong Pharmaceutical announced on the 10th that it has established the domestic...
|
‘FocusMed,’ a combined sales CSO invested by Geo-Young, is founded
A CSO(Contract Sales Organization)-type company invested by both multinational and domestic distribution companies has been launched.
According to the industry concerned on the 10th, FocusMed Korea, a combined sales ...
Shire led to the nullity of the trademark right, Hunterase, against Green Cross
Shire, a company that developed a hunter syndrome treatment ‘Elaprase(idursulfase),’ has succeeded in nullifying a trademark right called ‘Hunterase.’
‘Hunterase(idursulfase)’ developed by Green Cross is a hunter syn...
Pfizer vs. Hanmi from Norvasc to ChampixAs a rumor of registering anti-smoking treatments in the health insurance benefit this October at the earliest spreads, competition between ‘Champix(generic name: varenicline)’ ...
|
The impact of IMS Health Korea’s prosecution raises concerns of domestic pharmaceutical companies
As the pharmaceutical-related information provider, IMS Health Korea, is prosecuted for illegally collecting information, such as patient treatment records and prescription information, domestic pharmaceutical compani...
Hanmi Pharm established a $730 million worth license contract for an anticancer new drug with BoehringerHanmi Pharm(President Kwan-soon Lee) announced on the 28th that it established a license contract for its targeted lung cancer new drug(HM61713), which is being developed on its...
|
Boehringer replaces its head in 4 years with a new CEO appointed in October
Chief of Boehringer Ingelheim will be replaced in approximately 4 years.
According to the industry concerned on the 29th, CEO Dirk van Niekerk, who had led Boehringer Ingelheim Korea since May 2012, will leave the co...
Pharmaceutical and biopharmaceutical companies recorded the largest scale of IPOs ever in the first half of the year
It is estimated that the sizes of IPOs(Initial Public Offering) in the domestic healthcare industry will be the largest ever last year, approximately KRW 332.3 billion, increasing 142.8% up.
According to the NH Inves...
Biosimilars closed to commercialization challenges against a multinational company
Domestic biosimilar development companies, highly anticipated to acquire approvals soon, are underway to nullify patents and launch their products early.
In order to launch their products early, Samsung Bioepis and ...
